surmount-1 trial tirzepatide non-diabetic weight loss for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled With respect to the SURMOUNT-MAINTAIN

This dual mechanism drives its strong efficacy for weight loss (up to 22.5% body weight [1] reduction in the SURMOUNT-1 trial [1] ) and blood sugar control

If this sounds like something that might work for you, talk it over with your provider first

Eligibility criteria for tirzepatide Tirzepatide (Mounjaro) will not be accessible to everyone who wishes to use it

In 2023, the company generated solid YOY growth, with sales up 9% and expects to remain in a good position thanks to its robust pipeline

ZEPBOUND (tirzepatide) injection for subcutaneous use

The drug primarily increases insulin secretion and decreases glucagon secretion in a glucose-dependent manner